Tazobactum%25252525252525252525252525252525252520piperacillin

# Piperacillin-Tazobactam ## Overview Piperacillin-tazobactam is a combination penicillin-class antibiotic (ureidopenicillin) and a beta-lactamase inhibitor. It provides broad-spectrum coverage, including *Pseudomonas aeruginosa* and anaerobes. ## Primary Indications * Severe polymicrobial infections (intra-abdominal, skin and soft tissue, gynecologic). * Nosocomial pneumonia (HAP/VAP). * Febrile neutropenia. * Complicated urinary tract infections. ## Adult Dosing * **Standard dose:** 3.375 g (3 g piperacillin / 0.375 g tazobactam) IV every 6 hours. * **Severe infections:** 4.5 g (4 g piperacillin / 0.5 g tazobactam) IV every 6 hours. * **Extended/Continuous Infusion:** 4.5 g IV infused over 4 hours every 8 hours is often utilized in critically ill patients to maximize time above MIC. **Verify local institutional protocols.** * **Maximum Dose:** 18 g piperacillin/2.25 g tazobactam per 24 hours. ## Pediatric Dosing * **Neonates (≤ 40 weeks post-menstrual age):** Dosing is highly variable by gestational age; consult neonatal formulary (typically every 8–12 hours). * **Infants/Children (≥ 9 months) and Adolescents:** 80–100 mg/kg (piperacillin component) IV every 6–8 hours. * **Maximum:** Not to exceed adult dosing (4.5 g per dose). ## Dose Adjustments * **Renal Impairment:** Requires dose reduction or interval extension based on CrCl. * CrCl 20–40 mL/min: 2.25 g every 6 hours. * CrCl < 20 mL/min: 2.25 g every 8 hours. * **Hemodialysis:** 2.25 g after each dialysis session, plus a supplemental dose of 0.75 g after each dialysis. ## Contraindications * Hypersensitivity to piperacillin, tazobactam, or any beta-lactam (including cephalosporins/carbapenems due to potential for cross-reactivity). * History of anaphylaxis to penicillins. ## Adverse Effects * **Gastrointestinal:** Diarrhea, *C. difficile*-associated diarrhea. * **Hematologic:** Thrombocytopenia, leukopenia (common with prolonged therapy > 10–14 days). * **Dermatologic:** Rash, pruritus; rarely SJS/TEN. * **Neurologic:** Seizures (most commonly in patients with renal impairment or high doses). * **Other:** Injection site reactions, hypokalemia. ## Key Drug Interactions * **Aminoglycosides:** Potential for physical incompatibility in the IV line (administer at separate times/lines). * **Methotrexate:** May increase serum levels of methotrexate due to reduced renal excretion. * **Warfarin:** May enhance anticoagulant effect (monitor INR). * **Probenecid:** Increases serum concentrations of piperacillin. ## Monitoring * **Baseline/Routine:** Serum creatinine (for renal adjustment), CBC with differential (if duration > 10 days), and liver function tests. * **Clinical:** Resolution of signs of infection; monitor for signs of hypersensitivity or *C. difficile* infection. ## Clinical Pearls * **Pseudomonal Coverage:** Highly effective, but always check local antibiograms as resistance patterns vary widely. * **Renal Toxicity:** Some data suggest an increased risk of AKI when combined with vancomycin compared to vancomycin-cefepime combinations (often referenced in clinical literature regarding the "Vanc-Zosyn" interaction). * **Stability:** Once reconstituted, solutions should be used promptly. *** **Educational Disclaimer:** This information is for educational purposes only. Drug dosing, contraindications, and interaction profiles can change; always verify medication orders against current institutional protocols, professional guidelines, and the manufacturer’s full prescribing information before administration.